José Graça Moura Meireles

Dr. José Graça Moura Meireles

Centro Hospitalar Entre Douro e Vouga
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
RBRui Baptista
Rui Baptista
JMJosé Graça Moura Meireles
José Graça Moura Meireles
AAAna Agapito
Ana Agapito
GCGraça Castro
Graça Castro
ASAntónio Marinho da Silva
António Marinho da Silva
ARAbílio Reis
Abílio Reis
Introduction. Pulmonary arterial hypertension (PAH) is a rare disease that must be managed in specialized centers; therefore, the availability of epidemiological national data is critical.Methods. We conducted a prospective, observational, and multicenter registry with a joint collaboration from five centers from Portugal and included adult incident patients with PAH or chronic thromboembolic pulmonary hypertension (CTEPH).Results. Of the 79 patients enrolled in this study, 46 (58.2%) were classified as PAH and 33 patients (41.8%) as CTEPH. PAH patients had a mean age of 43.4 ± 16.4 years. Idiopathic PAH was the most common etiology (37%). At presentation, PAH patients had elevated right atrial pressure (RAP) (7.7 ± 5.9 mmHg) and mean pulmonary vascular resistance (11.4 ± 6.5 Wood units), with a low cardiac index (2.7 ± 1.1 L·min−1·m−2); no patient was under selective pulmonary vasodilators; however, at follow-up, most patients were on single (50%), double (28%), or triple (9%) combination vasodilator therapy. One-year survival was 93.5%, similar to CTEPH patients (93.9%), that were older (60.0 ± 12.5 years) and had higher RAP (11.0 ± 5.2 mmHg,P=0.015).Conclusions. We describe for the first time nationwide data on the diagnosis, management, and prognosis of PAH and CTEPH patients in Portugal. Clinical presentation and outcomes are comparable with those reported on other national registries.

1 January 2011 in Respiratory Medicine CME
Verified
Journal Article
Closed access
JMJosé Graça Moura Meireles
José Graça Moura Meireles
SNSara Neves
Sara Neves
ACAlexandra Castro
Alexandra Castro
MFMargarida França
Margarida França

26 July 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
ARAbílio Reis
Abílio Reis
JTJames Twiss
James Twiss
MVMargarida Vicente
Margarida Vicente
FGFabienne Gonçalves
Fabienne Gonçalves
LCLuísa Carvalho
Luísa Carvalho
LALuís Almeida
Luís Almeida
Patients with pulmonary arterial hypertension (PAH) and other forms of precapillary pulmonary hypertension (PH) have impaired quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a PH-specific patient-reported outcome measure that assesses symptoms, activity limitations and QoL. It was originally developed in UK-English. The main objective of this study was to create an adaptation of the CAMPHOR suitable for a Portuguese-speaking population. A multi-step approach was followed: bilingual and lay panel translation; cognitive debriefing interviews; and psychometric testing in repeated postal surveys (2 weeks apart) including assessment of internal consistency, reproducibility and validity. The Nottingham Health Profile (NHP) questionnaire was used as a comparator instrument to test convergent validity. The CAMPHOR was translated without difficulty by the two panels. Cognitive debriefing interviews showed the questionnaire was easily understood and considered relevant to patients’ experience with their illness. Psychometric evaluation was performed with 50 PAH patients (47 ± 14 years, 37 women). Cronbach’s alpha coefficients showed good internal consistency for the three CAMPHOR scales [Symptoms = 0.95; Activities = 0.93 and QoL = 0.94]. Test-retest coefficients showed that all scales had excellent reliability (Symptoms = 0.94; Activities = 0.89 and QoL = 0.93), indicating low levels of random measurement error. The CAMPHOR correlated as expected with the NHP. The magnitude of correlations followed a similar pattern to those in the original development study. The CAMPHOR also exhibited evidence of known group validity in its ability to distinguish between self-reported severity and general health groups. A valid and reliable version of the CAMPHOR questionnaire for the European Portuguese-speaking population was developed and is recommended for use.

30 September 2022 in Vascular Medicine
Verified
Journal Article
Closed access
MRMiguel Martín Romero
Miguel Martín Romero
VRVladimir Salazar Rosa
Vladimir Salazar Rosa
PRPablo Demelo Rodríguez
Pablo Demelo Rodríguez
AVAdriana Visonà
Adriana Visonà
ASAna I Farfán Sedano
Ana I Farfán Sedano
MMManuel Monreal
Manuel Monreal

15 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
MGMatteo Giorgi-Pierfranceschi
Matteo Giorgi-Pierfranceschi
MMManuel Monreal
Manuel Monreal
PIERPAOLO DI MICCOPIERPAOLO DI MICCO
PIERPAOLO DI MICCO
IFIria Francisco
Iria Francisco
Luis Manuel Hernández-BlascoLuis Manuel Hernández-Blasco
Luis Manuel Hernández-Blasco
TIthe RIETE Investigators
the RIETE Investigators
Background and Objectives: The influence of smoking habits on mortality, VTE recurrence, and major bleeding in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated. Materials and Methods: We used data from the RIETE (Registro Enfermedad TromboEmbólica) registry to compare mortality, VTE recurrence, and major bleeding risk in smoking versus non-smoking patients with acute VTE. Results: 50,881 patients (43,426 non-smoking and 7455 smoking patients) were included. After a median follow-up of 8.8 months, 7110 patients died (fatal PE 292 and fatal bleeding 281), 3243 presented VTE recurrence, and 1579 had major bleeding. At multivariate analysis, smoking behavior was associated with a higher hazard of death, (HR: 1.28; 95% CI: 1.19–1.40). The risk of VTE recurrence was marginally increased in smoking patients compared to non-smoking patients (1.14; 95% CI: 1.02–1.27). Major bleeding did not differ in smoking and non-smoking patients (1.15; 95% CI: 0.96–1.38). The presence of cancer did not appear to influence the association between smoking habits and death (HR: 1.34; 95% CI: 1.22–1.47 in cancer patients and HR: 1.23; 95% CI: 1.04, 1.45 in non-cancer patients, respectively) Conclusions: the risk of death after an acute episode of VTE appeared to be higher in smoking than in non-smoking patients and this risk is higher between patients presenting PE at the onset of symptoms.

1 January 2016
Verified
Dataset
Closed access
ARAbílio Reis
Abílio Reis
JTJames Twiss
James Twiss
MVMargarida Vicente
Margarida Vicente
FGFabienne Gonçalves
Fabienne Gonçalves
LCLuísa Carvalho
Luísa Carvalho
LALuís Almeida
Luís Almeida